Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine.

Mikami A, Ohtani H, Hori S, Sawada Y.

Int J Clin Pharmacol Ther. 2013 May;51(5):374-82. doi: 10.5414/CP201798.

PMID:
23357843
2.

[Interactions between metoprolol and antidepressants].

Molden E, Spigset O.

Tidsskr Nor Laegeforen. 2011 Sep 20;131(18):1777-9. doi: 10.4045/tidsskr.11.0143. Review. Norwegian.

4.

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.

Azuma J, Hasunuma T, Kubo M, Miyatake M, Koue T, Higashi K, Fujiwara T, Kitahara S, Katano T, Hara S.

Eur J Clin Pharmacol. 2012 Jan;68(1):29-37. doi: 10.1007/s00228-011-1094-4.

5.

Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol.

Parker RB, Soberman JE.

Pharmacotherapy. 2011 Jul;31(7):630-41. doi: 10.1592/phco.31.7.630.

PMID:
21923449
6.

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.

Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, McKillop D, Wild MJ.

Clin Pharmacokinet. 2005;44(10):1067-81.

PMID:
16176119
7.

Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.

Yoon YR, Cha IJ, Shon JH, Kim KA, Cha YN, Jang IJ, Park CW, Shin SG, Flockhart DA, Shin JG.

Clin Pharmacol Ther. 2000 May;67(5):567-76.

PMID:
10824636
8.

Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.

Lim KS, Cho JY, Jang IJ, Kim BH, Kim J, Jeon JY, Tae YM, Yi S, Eum S, Shin SG, Yu KS.

Br J Clin Pharmacol. 2008 Nov;66(5):660-6. doi: 10.1111/j.1365-2125.2008.03267.x.

9.
10.
11.

Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.

Kuhn UD, Kirsch M, Merkel U, Eberhardt AM, Wenda B, Maurer I, Härtter S, Hiemke C, Volz HP, Balogh A.

Int J Clin Pharmacol Ther. 2007 Jan;45(1):36-46.

PMID:
17256449
12.

Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.

Bramer SL, Suri A.

Clin Pharmacokinet. 1999;37 Suppl 2:41-51.

PMID:
10702886
13.

Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI).

Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L.

Eur J Clin Pharmacol. 2008 Mar;64(3):275-82.

PMID:
18043911
14.

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.

Laine K, Tybring G, Härtter S, Andersson K, Svensson JO, Widén J, Bertilsson L.

Clin Pharmacol Ther. 2001 Oct;70(4):327-35.

PMID:
11673748
15.

Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine.

Stout SM, Nielsen J, Welage LS, Shea M, Brook R, Kerber K, Bleske BE.

J Clin Pharmacol. 2011 Mar;51(3):389-96. doi: 10.1177/0091270010365559.

16.

Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.

Damy T, Pousset F, Caplain H, Hulot JS, Lechat P.

Fundam Clin Pharmacol. 2004 Feb;18(1):113-23.

PMID:
14748763
17.

Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.

Tsao YY, Gugger JJ.

Ann Pharmacother. 2009 Jul;43(7):1366-9. doi: 10.1345/aph.1M067.

PMID:
19531695
18.

Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.

Grönlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K.

Br J Clin Pharmacol. 2010 Jul;70(1):78-87. doi: 10.1111/j.1365-2125.2010.03653.x.

19.

Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.

Hamelin BA, Bouayad A, Méthot J, Jobin J, Desgagnés P, Poirier P, Allaire J, Dumesnil J, Turgeon J.

Clin Pharmacol Ther. 2000 May;67(5):466-77.

PMID:
10824625
20.

The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.

Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, Strabach G, van Gelderen M.

Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):43-52. doi: 10.1007/s13318-013-0133-1.

PMID:
23728524

Supplemental Content

Support Center